Paper39006993
Chemo-resistant Gestational Trophoblastic Neoplasia and the Use of Immunotherapy: A Case Report and Review of Literature.
Jacinto EK. Acta Med Philipp, 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Chemo-resistant Gestational Trophoblastic Neoplasia and the Use of Immunotherapy: A Case Report and Review of Literature. Papers, record 39006993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39006993
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Chemo-resistant Gestational Trophoblastic Neoplasia and the Use of Immunotherapy: A Case Report and Review of Literature.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29059432 | A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer. | J Natl Cancer Inst | 2017 | https://conductscience.org/library/papers/29059432 | PubMed |
| 2 | 26760424 | Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. | Cochrane Database Syst Rev | 2016 | https://conductscience.org/library/papers/26760424 | PubMed |
| 3 | 32964090 | Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: A case for immune checkpoint salvage therapy in trophoblastic tumors. | Gynecol Oncol Rep | 2020 | https://conductscience.org/library/papers/32964090 | PubMed |
| 4 | 29442540 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29442540 | PubMed |
| 5 | 25550880 | Epithelioid trophoblastic tumor after induced abortion with previous broad choriocarcinoma: a case report and review of literature. | Int J Clin Exp Pathol | 2014 | https://conductscience.org/library/papers/25550880 | PubMed |
| 6 | 32297899 | Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32297899 | PubMed |
| 7 | 33948476 | Vaginal mucositis related to immunotherapy in endometrial cancer. | Gynecol Oncol Rep | 2021 | https://conductscience.org/library/papers/33948476 | PubMed |
| 8 | 34145099 | Predictors of chemotherapy resistance & relapse in gestational trophoblastic neoplasia. | Indian J Med Res | 2020 | https://conductscience.org/library/papers/34145099 | PubMed |
| 9 | 31569067 | Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia. | Eur J Cancer | 2019 | https://conductscience.org/library/papers/31569067 | PubMed |
| 10 | 9826467 | Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen. | Gynecol Oncol | 1998 | https://conductscience.org/library/papers/9826467 | PubMed |
| 11 | 33634869 | Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer. | Int J Cancer | 2021 | https://conductscience.org/library/papers/33634869 | PubMed |
| 12 | 35627534 | Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study. | Int J Environ Res Public Health | 2022 | https://conductscience.org/library/papers/35627534 | PubMed |
| 13 | 32395603 | A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab. | Gynecol Oncol Rep | 2020 | https://conductscience.org/library/papers/32395603 | PubMed |
| 14 | 27362903 | PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. | Int J Gynecol Pathol | 2017 | https://conductscience.org/library/papers/27362903 | PubMed |
| 15 | 25547507 | Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25547507 | PubMed |
| 16 | 34258357 | Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report. | Gynecol Oncol Rep | 2021 | https://conductscience.org/library/papers/34258357 | PubMed |
| 17 | 29185430 | Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. | Lancet | 2017 | https://conductscience.org/library/papers/29185430 | PubMed |
| 18 | 34624252 | Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34624252 | PubMed |
| 19 | 28742453 | Complete Serologic Response to Pembrolizumab in a Woman With Chemoresistant Metastatic Choriocarcinoma. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28742453 | PubMed |
| 20 | 28881921 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Ann Oncol | 2017 | https://conductscience.org/library/papers/28881921 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41627371 | Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity. | Adv Ther | 2026 | https://conductscience.org/library/papers/41627371 | PubMed |
| 40323395 | Clinical routine care for choriocarcinoma: a descriptive analysis of data from the Baden-Wuerttemberg Cancer Registry (BWCR). | Arch Gynecol Obstet | 2025 | https://conductscience.org/library/papers/40323395 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CGB5 | 93659 | PubTator's text mining | https://conductscience.org/library/genes/93659 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39006993
GET https://conductscience.org/api/papers/v1/39006993/references?page=2